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Abstract 
Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing events 
that affects the quality of life of cancer patients. Evidence suggests that females are more 
susceptible to CINV than males, but the mechanism remains unknown. The current thesis 
examined whether higher levels of circulating estrogens in females contributes to this sex 
difference. CINV was analyzed in a pediatric oncology population, where it was revealed 
female patients demonstrate increased delayed CINV relative to male patients, in the post-
pubertal age group. CINV was also studied by examining the influence of the estrous cycle 
on anticipatory nausea (AN) in rats. This study showed that rats in proestrus demonstrate 
increased AN relative to rats in diestrus. These results imply that females’ greater likelihood 
to experience CINV may be partly due to their higher levels of circulating estrogens. 
Uncovering this mechanism will ultimately help to alleviate the burden of CINV on cancer 
patients.  
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Chapter 1 
1 General introduction 
The prevalence, course, and severity of many medical and behavioural conditions differ 
between males and females (Manton, 1999; Regitz-Zagrosek & Seeland, 2013). These 
sex differences arise from a combination of genetic, hormonal, and social factors that 
interact to produce widespread differences in the brain and behaviour of the human 
population. Despite knowledge of these sex differences, there is little sex-specific 
healthcare; sex and gender are often not taken into account when considering the 
prevention, treatment, and management of disease (Regitz-Zagrosek, 2012). Moreover, 
many animal studies are carried out with male subjects only, thus largely ignoring crucial 
sex differences. It is critical that researchers and clinicians take sex into account, as there 
are many questions concerning sex differences that have yet to be answered. Though sex 
differences in various diseases and conditions have been discovered, the mechanisms 
behind many of these sex differences remain largely unclear. Knowledge of these 
mechanisms is essential for the employment of more effective and personalized treatment 
strategies for many disorders that differentially affect males and females. 
One area that has garnered recent interest is sex differences in the experience of nausea 
and nausea-related phenomena (Cloutier, Kavaliers, & Ossenkopp, 2017; Hilarius et al., 
2011; Paillard et al., 2013). In a study identifying risk factors for post-operative nausea 
and vomiting (PONV), female sex was identified as the strongest patient-related predictor 
(Fujii, 2009; Gan, 2006). Female sex is also a known risk factor for motion sickness 
susceptibility (Paillard et al., 2013). Moreover, motion sickness has been shown to 
fluctuate throughout the menstrual cycle, in accordance with fluctuating estrogen levels 
(Golding, Kadzere, & Gresty, 2005). Women also report different factors which 
contribute to chronic migraine compared to men, with one of the more prevalent factors 
in women being nausea (Özge & Yalın, 2016). There is also a notable sex difference in 
the symptomatology reported during acute coronary syndromes. Females are more likely 
than males to report nausea, vomiting, and abdominal pain (Arslanian-Engoren, & 
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Engoren, 2010; Shin, Martin, & Suls, 2010). Finally, and critical to the present thesis, 
female sex is a known risk factor for chemotherapy-induced nausea and vomiting (CINV) 
(Molassiotis, Stamataki, & Kontopantelis, 2013; Sekine, Segawa, Kubota, & Saeki, 2013; 
Warr, 2014). Female patients experience CINV at higher frequencies than male patients 
in the acute, delayed, and anticipatory phases (Gonella & Di Giulio, 2015). In the delayed 
phase specifically, female sex is the only patient-related risk factor (Sekine et al., 2013).  
Though the mechanism responsible for the sex difference in nausea-related phenomena 
has yet to be discovered, there is some evidence that implicates estrogens. The present 
thesis explored the possible influence of estrogens on CINV, and on anticipatory nausea 
(AN), which is a specific syndrome related to CINV. Two diverse study methodologies 
were used. The first consisted of a post hoc data analysis of pediatric oncology patients, 
examining sex differences in CINV in these patients at various developmental stages. The 
second study employed an animal model of AN which examined differences in 
conditioned disgust behaviours in female rats between two of the four phases of the 
estrous cycle.  
There is no shortage of research in this area using solely male subjects. Unfortunately, 
inferences are often drawn from these studies that are applied to both males and females, 
which largely ignores the influence of female physiology and biology. The present thesis 
focused on female subjects, and the putative contribution of estrogens to CINV.  
1.1 Chemotherapy-induced nausea and vomiting (CINV) 
Cancer patients undergoing chemotherapy list nausea and vomiting as among the most 
debilitating and distressing treatment-related adverse effects (Aapro, Molassiotis, & 
Olver, 2005; Molassiotis, 2005). Chemotherapy-induced nausea and vomiting (CINV) is 
associated with significant deterioration of quality of life for these patients, and remains a 
severe problem in the oncology community (Feinberg, Gilmore, Haislip, Wentworth, & 
Burke, 2010). CINV can be acute (24 hours following chemotherapy administration), 
delayed (more than 24 hours after and within 7 days of chemotherapy administration), or 
anticipatory (within 24 hours prior to chemotherapy administration).  
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For adults undergoing chemotherapy, there are a number of known risk factors associated 
with CINV. These include: age below 55 years, female sex, non-habitual alcohol use, and 
history of nausea including pregnancy-related morning sickness and motion-sickness 
(Molassiotis et al 2013; Sekine et al., 2013; Warr, 2014). Taking these risk factors into 
account when selecting CINV prophylaxis for individual patients may improve complete 
CINV control rates. Unfortunately, in children, risk factors for the development of CINV 
are currently unknown. Although there are several possible risk factors, the present thesis 
focused on one potential risk factor in children: female sex. Knowledge of patient-related 
risk factors for CINV would permit tailoring of standard CINV prophylaxis to meet the 
needs of individual children and would likely result in complete CINV control in a higher 
proportion of children. In the present thesis, patients were split into three groups: pre-, 
mid-, and post-pubertal, in order to pinpoint exactly when the sex difference in CINV 
may arise.  
One stage of CINV that is particularly challenging to study is anticipatory CINV. 
Anticipatory CINV is the experience of nausea and vomiting in the 24 hours leading up 
to chemotherapy administration, in anticipation of the treatment itself. Anticipatory 
CINV is difficult to control once it develops, and it does not respond well to 
pharmacological or non-pharmacological treatment strategies (Tyc, Mulhern, Barclay, 
Smith, & Bieberich, 1997). Currently, the best treatment of anticipatory CINV is to 
prevent it from occurring in the first place, by controlling acute and delayed CINV (Chan 
et al., 2015). The prevalence of anticipatory CINV reported in the literature ranges from 
8%–30% of patients (Molassiotis et al., 2016; Morrow et al., 1998).  It is posited that 
anticipatory CINV develops through classical conditioning (Bovbjerg, 2006; Stockhorst, 
Steingrueber, Enck, & Klosterhalfen, 2006). The chemotherapy acts as the unconditioned 
stimulus, which elicits nausea and vomiting, the unconditioned response. The physical 
hospital or room acts as the conditioned stimulus and after repeated pairings, these 
environmental stimuli alone can elicit nausea and vomiting (Tyc et al., 1997). The 
prevalence and severity of anticipatory CINV are the basis for the development of an 
animal model (Limebeer et al., 2006; 2008). 
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1.2 Animal model 
A rat model of anticipatory CINV has been well established and is used as a preclinical 
tool to study possible treatments (Limebeer et al., 2006; 2008). This model refers to the 
condition as anticipatory nausea (AN; Limebeer et al., 2006; 2008). The AN model uses 
the toxin, lithium chloride (LiCl), a nausea-inducing drug, as the unconditioned stimulus, 
and a distinctive context as the conditioned stimulus. This paradigm demonstrates rats’ 
ability to associate toxin-induced nausea with the context in which they experienced it. 
Rats are injected with LiCl and placed in a distinctive context immediately after injection. 
After numerous pairings, rodents are capable of associating this distinctive context with 
“feelings” of nausea. When rodents are re-exposed to the context drug-free, they will 
demonstrate a conditioned-gaping response, which is a learned response. This well-
established animal model is a valuable pre-clinical tool for examining possible risk 
factors and treatments for AN (Cloutier et al., 2017; Limebeer et al., 2006; 2008). 
Sex differences have been observed in this animal model. On drug-free test day, female 
rats demonstrate significantly more conditioned gaping responses than male rats (Cloutier 
et al., 2017). This is consistent with other animal studies; sex differences in favour of 
females have been seen in the development of motion-sickness in the musk shrew (Javid 
& Naylor, 1999), as well as in many clinical studies that point to female sex as a risk 
factor for a number of nausea-related phenomena (Arslanian-Engoren, & Engoren, 2010; 
Fujii, 2009; Gan, 2006), including CINV (Molassiotis et al., 2013; 2016).  
1.3 Estrogens 
Although this sex difference is well established, further exploration is necessary to 
examine the mechanism underlying this sex difference. It has been suggested that 
gonadal hormones, specifically estrogens, play a role in this etiology. Estradiol has been 
shown to have some natural illness-inducing properties (Ganesan & Simpkins, 1991; 
Goodman & Gilman, 1975). When paired with a novel sucrose taste, estradiol produces a 
conditioned taste avoidance and disgust response to the novel taste (Ossenkopp, Rabi, & 
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Eckel, 1996). Estradiol can also have an additive effect on the LiCl-induced conditioned 
disgust in castrated male rats (Lin, Tsai, Tai, & Yeh, 2015).  
Estrogens also have stimulatory effects on the serotonergic system. Acute estradiol 
administration to ovariectomized rats increases serotonin levels in a number of brain 
regions, including the hippocampus (Johnson & Crowley, 1983). Evidence suggests that a 
large number of estrogen receptors are expressed in the dorsal raphe nuclei, where most 
serotonin neurons are located (Merchenthaler, Lane, Numan, & Dellovade, 2004). 
Consequently, estrogen replacement increases neuronal activity in this this region 
(Dalmasso, Amigone, & Vivas, 2011). Serotonin (specifically 5-HT3) antagonism has 
well-established anti-emetic effects, thus implicating the serotonergic system in the 
production of nausea and vomiting (Hesketh, 2000). Therefore, estrogens may increase 
nausea and vomiting through a downstream serotonergic process. 
There is some indication of an evolutionary explanation for estrogen’s enhancing effect 
on nausea. It has been proposed that nausea and vomiting during pregnancy evolved as an 
evolutionarily adaptive mechanism to avoid the ingestion of harmful toxins, thus 
potentially harming the fetus (Buss, 1999; Profet, 1995). The vomiting and disgust 
reflexes have long been regarded as evolutionarily adaptive, as they protect the individual 
from ingesting potentially poisonous or noxious substances. It is possible that estrogen 
causes this sense to be particularly heightened in women, who have the added 
responsibility of protecting their developing offspring from harm (Sherman & Flaxman, 
2002).  
Estrogens are a class of hormones that naturally fluctuate through the course of a 
woman’s lifetime. Estrogens begin to rise during puberty, fluctuate throughout the 
menstrual cycles, and begin to decline after menopause. Thus, it is possible to observe 
estrogen’s effects on nausea by examining the course of nausea-related phenomena in 
different stages of the lifespan of a woman. Motion sickness has been shown to fluctuate 
throughout the menstrual cycle, in accordance with fluctuating estrogen levels (Golding, 
Kadzere, & Gresty, 2005). Additionally, motion sickness susceptibility and chronic 
migraine demonstrate age-dependent decreases in the experience of nausea in women but 
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not men. After menopause, motion sickness susceptibility decreases and nausea no longer 
predicts chronic migraine (Özge et al, 2014; Paillard et al., 2013).   
1.4 Objectives of the current thesis 
The first objective of this thesis was to explore the association between CINV control as 
assessed by pediatric oncology patients and/or their parents and the patient-related factors 
of sex and pubertal status. The study involved a post hoc analysis using integrated data 
from three prospective, observational studies which examined acute, delayed, and 
anticipatory CINV in pediatric oncology patients at The Hospital for Sick Children 
(SickKids) in Toronto. The study explored sex differences in pre-, mid-, and post-
pubertal children in order to elucidate the possibility that sex differences in CINV only 
arise post pubertally.  
The second objective of this thesis was to examine the ability of female rodents to 
process and associate a distinctive context with an internal sickness cue (i.e., LiCl-
induced nausea) in the rodent model of AN, and to test whether estrous cycle phase 
influences the formation of AN. Specifically, using a conditioned disgust paradigm, 
female rats conditioned and tested during proestrus (high estrogen levels) were compared 
to those conditioned and tested during diestrus (low estrogen levels) to determine if 
estrogen is modulating the observed sex difference in the literature. 
The current study examined sex differences in CINV by considering two very different 
subject groups. In Chapter 2, pediatric patients were examined, while in Chapter 3, adult 
female rats were the subjects. Much of the sex differences in CINV literature focuses on 
adult patients, while the pediatric population has been less investigated. The present study 
focused on this less examined patient age group, in order to shed some light on the 
possible sex differences that may or may not be present in this population.  
Although it has been well established that females are more likely to develop CINV 
(including but not limited to the anticipatory phase), further research is necessary to 
determine the mechanism contributing to this sex difference. It was hypothesized that 
estrogen is the contributing factor to females’ greater propensity to experience CINV than 
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their male counterparts. This hypothesis was explored through diverse studies, uniquely 
combining human and rodent subjects, whose results will strengthen the estrogen 
hypothesis with converging evidence.  
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Chapter 2 
2 Examining the Association Between Sex, Pubertal 
Status, and the Development of Chemotherapy-Induced 
Nausea and Vomiting (CINV) in Pediatric Oncology 
Patients 
2.1 Introduction  
Cancer patients undergoing chemotherapy list nausea and vomiting as among the most 
debilitating and distressing treatment-related adverse effects (Aapro, Molassiotis, & 
Olver, 2005; Molassiotis, 2005). Chemotherapy-induced nausea and vomiting (CINV) is 
associated with significant deterioration of quality of life for these patients, and remains a 
severe problem in the pediatric oncology community (Feinberg, Gilmore, Haislip, 
Wentworth, & Burke, 2010). CINV can be acute (24 hours following chemotherapy 
administration), delayed (more than 24 hours after and within 7 days of chemotherapy 
administration), or anticipatory (within 24 hours prior to chemotherapy administration). 
Despite the routine administration of modern CINV prophylaxis based on the emetic risk 
carried by the planned chemotherapy regimen, up to 55% of children receiving 
moderately or highly emetogenic chemotherapy experience CINV (Kang et al., 2015, 
Kovacs et al., 2016). Chemotherapy-induced nausea (CIN) and chemotherapy-induced 
vomiting (CIV) are considered as separate entities and are often analyzed separately. 
While modern antiemetics have vastly improved CIV control rates over the past decade, 
CIN remains more difficult to measure, as well as to control (Rapoport, Molasiotis, 
Raftopoulos, & Roila, 2015). 
For adults undergoing chemotherapy, there are a number of known risk factors associated 
with CINV. Taking these risk factors into account when selecting CINV prophylaxis for 
individual patients may improve complete CINV control rates. These risk factors include: 
age (below 55 years), non-habitual alcohol use, past history of nausea including 
pregnancy-related morning sickness and motion-sickness, and female sex (Molassiotis, 
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Stamataki, & Kontopantelis, 2013; Sekine, Segawa, Kubota, & Saeki, 2013; Warr, 2014). 
Female patients experience CINV at higher frequencies than male patients in both the 
acute and delayed phases (Gonella & Di Giulio, 2015). In the delayed phase specifically, 
female sex is the only patient-related risk factor (Sekine et al., 2013). Although clinicians 
are aware of this, the mechanism by which this sex difference operates remains unclear. 
Sex differences in favour of females have also been seen in post-operative nausea and 
vomiting as well as susceptibility to motion sickness (Fujii, 2009; Paillard et al., 2013). 
It has been suggested that sex hormones, specifically estrogens, may play a role in CINV. 
Several animal studies have shown that estrogens enhance conditioned aversion 
behaviour and may increase nausea and malaise (Fudge, Kavaliers, Baird, & Ossenkopp, 
2009; Ganesan, 1994). Estradiol itself has been found to produce both conditioned taste 
avoidance when paired with a novel sucrose taste, as well as a strong shift in palatability 
of the sucrose taste (Ossenkopp, Rabi, & Eckel, 1996). This may occur because of 
estradiol’s illness-inducing properties, which has been seen in animal studies (Ganesan & 
Simpkins, 1991) as well as in humans (Goodman & Gilman, 1975). 
Although investigators have observed signals that CINV is more problematic in adult 
females compared to adult males, a sex difference in pediatric populations is less evident 
(Freedman et al., 2014). As of now, chemotherapy emetogenicity is the strongest known 
determinant of CINV in children. While recent pediatric CINV studies have not found 
female sex to be a significant predictor, these studies have not taken pubertal status into 
consideration when examining sex differences (Aseeri, Mukhtar, Khansa, Elimam, & 
Jastaniah, 2013; Dupuis et al., 2017; Holdsworth, Raisch & Frost, 2006; Vol et al., 2016).  
If in fact gonadal hormones such as estrogens contribute to the sex difference in adults, it 
is possible that a sex difference has not been seen in the pediatric population due to the 
relatively low levels of circulating gonadal hormones in children. The present study 
specifically differentiated pubertal status to examine the possibility that sex differences in 
CINV only arise post puberty. It was hypothesized that sex differences would only appear 
in patients in the post pubescent group.  
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The present study involved a post hoc analysis using integrated data from three 
prospective, observational studies which examined acute, delayed, and anticipatory CINV 
in pediatric oncology patients at The Hospital for Sick Children (SickKids) in Toronto. 
The primary objective of this study was to explore the association between CINV control 
as assessed by patients and/or their parents and the patient-related factors of sex and 
pubertal status. Any sex differences found (or lack thereof) may then be used by 
clinicians to personalize CINV prophylaxis provided to children receiving chemotherapy. 
Finding a post pubertal CINV sex difference would also point to a role for gonadal 
hormones in the observed sex difference in CINV seen in adults.  Finally, knowledge of 
patient-related risk factors for CINV would permit tailoring of standard CINV 
prophylaxis to meet the needs of individual children and would likely result in more 
complete CINV control in a higher proportion of children.  
2.2 Method 
Data for the current analysis were pooled from three prospective, observational studies 
completed at SickKids. The three studies included in this post hoc analysis are outlined in 
Table 2.1. All studies collected information on the prevalence of acute, delayed, and 
anticipatory CINV in children receiving chemotherapy. All studies were approved by the 
SickKids Research Ethics Board. The following is a brief overview of the study 
methodology. For more detailed descriptions, see the methodologies from the original 
studies (Flank et al., 2017a; Flank et al., 2017b; Vol et al., 2016). 
2.2.1 Patients 
Data were collected from 160 patients (105 male and 55 female, ages 4 to 18, M= 9.56 
years, SD= 3.90 years). Common eligibility criteria in all three studies were as follows: 
patients had to have been English speaking, and have the cognitive ability believed to be 
at least at a 4-year-old level according to a parent or health care professional. Informed 
consent was obtained from eligible patients aged 16 years or older. For eligible patients 
younger than 16 years, informed consent was obtained from the parent or guardian and,  
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Table 2.1  
Summary of Studies Used in Post Hoc Analysis 
	
Study N  
(m:f) 
Additional Eligibility Criteria 
aChemotherapy-
induced nausea and 
vomiting in children 
receiving ifosfamide 
plus etoposide, 
dactinomycin plus 
vincristine, high dose 
methotrexate, or high 
dose methotrexate plus 
vincristine 
36 
(23:13) 
- Receiving ifosfamide 1800mg/m2/day plus etoposide 
100mg/m2/day, dactinomycin 45µg/kg/dose plus 
vincristine 1.5mg/m2/dose, methotrexate >1g/m2, 
methotrexate >1g/m2 plus vincristine 1.5mg/m2/dose 
or equivalent in cases of dose reduction in response 
to renal or hepatic impairment 
 
bPrevalence of 
chemotherapy-induced 
nausea and vomiting in 
children receiving 
hematopoietic stem cell 
transplantation 
conditioning (HSCT) 
54 
(31:23) 
- Receiving HSCT conditioning for their first HSCT 
for any indication other than immunodeficiency 
- HSCT conditioning regimen started at The Hospital 
for Sick Children 
 
cChemotherapy-
induced nausea and 
vomiting in children 
receiving intrathecal 
methotrexate 
with/without vincristine 
 
70 
(51:19) 
- Receiving intrathecal methotrexate in the context of 
maintenance therapy for acute lymphoblastic 
leukemia and as dosed by age per protocol. Patients 
also received their protocol driven maintenance 
chemotherapy which includes oral 6 mercaptopurine 
and may include IV vincristine and an oral steroid 
pulse (prednisone or dexamethasone).   
- Patients were past their first cycle of maintenance 
therapy to avoid interactions with the intensive 
chemotherapy phase 
- Not receiving chemotherapy other than dictated by 
protocol for maintenance therapy within 24 hours 
prior to or 24 hours following receipt of intrathecal 
methotrexate	
 
a Vol, H., Flank, J., Lavoratore, S. R., Nathan, P. C., Taylor, T., Zelunka, E., . . . Lee Dupuis, L. (2016). Poor 
chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose 
methotrexate. Supportive Care in Cancer, 24(3), 1365-1371.  
b Flank, J., Sparavalo, J., Vol, H., Hagen, L., Stuhler, R., Chong, D,, Courtney, S., Doyle, J. J., Gassas, A., Schechter, 
T., Dupuis, L. L. (2017b). The burden of chemotherapy-induced nausea and vomiting in children receiving 
hematopoietic stem cell transplantation conditioning: a prospective study. submitted for publication 
c Flank, J., Nadeem, K., Moledina, S., Khanna, M., Schindera, C., Punnett, A. S., Dupuis, L. L. (2017a). Nausea and 
vomiting in children and adolescents receiving intrathecal methotrexate: a prospective, observational study. submitted 
for publication 
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in the case of children aged 7-15 years, assent was obtained from the child as well. See 
Table 2.1 for additional eligibility criteria for each study.  
2.2.1.1 Pubertal status designation  
Pubertal status of each participant was defined using sex-specific age cut-offs, based on 
norms for precocious and late onset puberty in the literature (Carel, Lahlou, Roger, & 
Chaussain, 2004; Sedlmeyer & Palmart, 2002). Males between the ages of 1 to 9 years 
were defined as “pre-pubertal”, between 9.1 to 14 years as “mid-pubertal”, and between 
14.1 to 18 years as “post-pubertal”. Females between the ages of 1 to 8 years were 
defined as “pre-pubertal”, between 8.1 to 13 years as “mid-pubertal”, and between 13.1 
to 18 years as “post-pubertal”. See Table 2.2 for sample size of each of these pubertal 
groups.  
2.2.2 Data collection 
Structured diaries were used to collect CINV data. A validated nausea assessment 
instrument, the pediatric nausea assessment tool (PeNAT; Dupuis, Taddio, Kerr, Kelly, & 
MacKeigan, 2006), was used to measure nausea. The PeNAT, which has been validated 
for children aged 4 to 18 years, incorporates a facial expression scale with a standard 
script. Through the use of the facial scale and script, children can focus on the expression 
being asked of them and select the facial expression that best describes their feelings. 
Nausea is then translated onto a Likert scale from 1 to 4 (1 being no nausea to 4 being 
worst nausea) (Dupuis et al., 2006). Emetic episodes as well as antiemetic administration 
were also recorded in the diaries. Vomiting was defined as the expulsion of any stomach 
contents by the mouth. Retching was defined as an attempt to vomit that is not productive 
of any stomach contents. An emetic episode was defined as a vomit or retch separated 
from another vomit or retch by at least 1 minute. A study investigator explained study 
procedures to each patient and/or parent or guardian and administered the PeNAT to the 
child at least once in the presence of the parent or guardian. The number of emetic 
episodes recorded by the child/parent/guardian was compared against the nursing flow  
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Table 2.2 
Sample Size By Pubertal Status and Sex 
   
  
Pre Pubertal 
 
Mid Pubertal 
 
Post Pubertal 
 
 
Totals 
 
Males 
 
 
52 
 
43 
 
10 
 
105 
 
Females 
 
 
26 
 
13 
 
16 
 
55 
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sheets for inpatients, and in the case of discrepancy, the higher number was used. All 
diary pages completed during the inpatient period were collected prior to discharge. The 
diary pages completed during the outpatient period were returned to the investigator via 
mail or in person at a subsequent hospital visit. 
2.2.3 Outcomes 
2.2.3.1 Anticipatory CINV 
Anticipatory CINV was defined as nausea, vomiting, or retching in the 24 hours prior to 
chemotherapy administration in patients that have received chemotherapy previously. 
The child was asked if he/she felt nauseated or vomited in the last 24 hours before his/her 
first chemotherapy dose in the study course. The parent(s)/guardian(s) were asked 
separately if their child vomited or felt nauseated within the last 24 hours before his/her 
first chemotherapy dose in the course to confirm the information provided by the child. 
Anticipatory CINV was quantified by presence or absence.  
2.2.3.2  Acute and delayed phase CINV 
Acute CINV was defined as nausea, vomiting, or retching occurring within 24 hours 
following chemotherapy administration. Delayed CINV was defined as nausea, vomiting, 
or retching which occurs between 25 hours up to 7 days following chemotherapy 
administration. The time that each emetic episode occurred was recorded by the child or 
parent in the diary. Children were able to rank nausea as none, mild, moderate, or severe 
using the PeNAT. Both acute and delayed CINV were quantified with a score of “level of 
control over CINV” (Likert scale of 1-3, 1 being complete control, 2 being partially 
controlled, 3 being uncontrolled). The primary study endpoint was complete control of 
CINV which was defined as no nausea (maximum PeNAT score of 1) and no emetic 
episodes. Partial CINV control was defined as a maximum PeNAT score of 2 during the 
phase of interest, or 1 or 2 emetic episodes in any 24-hour period. Uncontrolled CINV was 
defined as a maximum PeNAT score of 3 or 4 during the phase of interest, or more than 2 
emetic episodes in any 24-hour period. 
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2.2.4 Data analysis 
Dependent variables quantified were the proportion of participants that developed 
anticipatory CIN, CIV, and CINV, the overall level of control of acute CIN, CIV, and 
CINV, and the overall level of control of delayed CIN, CIV, and CINV. Independent 
variables examined were sex (male and female) and pubertal status (pre-pubertal, mid-
pubertal, and post-pubertal). All statistical tests used α=0.05 as a significance criterion. 
Statistical analysis were performed using IBM SPSS Statistics 23 for Windows. 
2.2.4.1 Anticipatory CINV 
Data was analyzed using three separate chi-square tests to explore the association 
between sex and proportion of patients who develop anticipatory CIN, CIV, and CINV, 
for each of the three pubertal groups of interest. 
2.2.4.2 Acute and delayed phase CINV 
Data was analyzed using 2 X 3 between subjects analysis of variances (ANOVA) with 
two between subject factors of Sex (at two levels: male and female) and Pubertal Status 
(at three levels: pre-pubertal, mid-pubertal, and post-pubertal) for CIN, CIV, and CINV 
each separately. This analysis compared mean CINV control scores (higher indicating 
increased CINV) for each of the groups of interest. A priori planned comparisons were 
performed on each pubertal group separately, as this was the specific focus of the study. 
This was done using three separate one-way ANOVAs on each pubertal group, with one 
between subject factor of sex (at two levels: male and female).  
The number of individuals experiencing either completely controlled, partially controlled, 
or uncontrolled CINV were also calculated as a proportion of total in each group of 
interest (pre-pubertal males, pre-pubertal females, mid-pubertal males, mid-pubertal 
females, post-pubertal males, and post-pubertal females). This was done separately for 
anticipatory, acute, and delayed CINV. Subsequently, chi square analyses were 
performed to compare these frequencies, to further ascertain if sex differences exist in 
level of control of CINV in each pubertal group.  
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2.3 Results 
2.3.1 Anticipatory CIN, CIV, and CINV 
Three separate chi-square analyses revealed no significant differences between males and 
females for any of the pubertal groups. The proportion of children experiencing 
anticipatory CINV in each of the pubertal groups is shown in Table 2.3. For all pubertal 
groups, no relationship was found between sex and development of CIN, CIV, or CINV.   
2.3.2 Acute CIN, CIV, and CINV control  
The proportion of children who experienced complete, partial, or no control of CIN, CIV, 
and CINV in the acute phase is summarized in Table 2.4. The 2 X 3 between-subjects 
ANOVA revealed no significant Sex or Pubertal Status effects for acute CIN, CIV, or 
CINV. Since pubertal status was of particular interest in this study, a priori planned 
comparisons were done in order to explore possible Sex effects in each of the pubertal 
status groups. The one-way ANOVA revealed no significant Sex effect in any of the 
pubertal status groups. The chi square analyses also revealed no significant differences in 
any of pubertal groups for acute CIN, CIV, and CINV control.  
2.3.3 Delayed CIN, CIV, and CINV control  
The proportion of children who experienced complete, partial, or no control of CIN, CIV, 
and CINV in the delayed phase is summarized in Table 2.5. For CIV, the 2 X 3 between 
subjects ANOVA revealed a significant main effect of Sex, F(1,154)= 7.76, p < .01. For 
CIN and CINV, the 2 X 3 between-subjects ANOVA revealed no significant Sex or 
Pubertal Status effects. Since pubertal status was of particular interest in this study, a 
priori planned comparisons were done in order to explore possible Sex effects in each of 
the pubertal status groups. For both CIN and CINV, the one-way ANOVA revealed a 
significant main effect of Sex in the post pubertal group, F(1,24)= 5.01, p < .05. As 
shown in Figure 2.1, post pubertal females demonstrated a significantly higher mean 
“level of control of delayed CINV” score, which translates to higher levels of  
		
23 
Table 2.3 
Prevalence of Anticipatory CINV by Sex and Pubertal Status 
  
Number of patients experiencing anticipatory chemotherapy-induced 
nausea and vomiting (%) 
  
CINV 
       
CIV 
  
CIN 
  
Male 
 
Female 
  
Male 
 
Female 
  
Male 
 
Female 
Pre Pubertal 8 (15) 5 (19)  4 (8) 2 (8)  8 (15) 5 (19) 
Mid Pubertal 9 (21) 2 (15)  5 (12) 2 (15)  7 (16) 2 (15) 
 
Post Pubertal 1 (10) 5 (31)  0 (0) 2 (13)  1 (10) 4 (25) 
CINV chemotherapy-induced nausea and vomiting, CIV chemotherapy-induced 
vomiting, CIN chemotherapy-induced nausea. 
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Table 2.4 
Prevalence of Acute CINV by Sex and Pubertal Status 
  
Acute Phase  
  
CINV 
       
CIV 
  
CIN 
  
Male 
 
Female 
  
Male 
 
Female 
  
Male 
 
Female 
Number of patients 
experiencing 
complete controla 
(%) 
        
 
Pre Pubertal 14 (27) 10 (38)  38 (73) 17 (65)  14 (27) 11 (42) 
 
Mid Pubertal 14 (33) 2 (15)  26 (60) 5 (38)  14 (33) 2 (15) 
 
Post Pubertal 1 (10) 3 (19)  7 (70) 9 (56)  1 (20) 3 (19) 
 
Number of patients 
experiencing 
partial controlb (%) 
        
 
Pre Pubertal 16 (31) 4 (15)  7 (13) 3 (12)  17 (33) 5 (19) 
 
Mid Pubertal 11 (26) 4 (31)  9 (21) 6 (46)  11 (26) 4 (31) 
 
Post Pubertal 4 (40) 4 (25)  2 (20) 3 (19)  4 (40) 4 (25) 
 
Number of patients 
experiencing no 
controlc (i.e. 
uncontrolled) (%) 
        
Pre Pubertal 22 (42) 12 (46)  7 (13) 6 (23)  21 (40) 10 (38) 
 
Mid Pubertal 18 (42) 7 (54)  8 (19) 2 (15)  18 (42) 7 (54) 
 
Post Pubertal 5 (50) 9 (56)  1 (10) 4 (25)  5 (50) 9 (56) 
 
CINV chemotherapy-induced nausea and vomiting, CIV chemotherapy-induced 
vomiting, CIN chemotherapy-induced nausea. 
a Complete control is defined as a max PeNAT score of 1 and/or 0 vomits, retches, or 
gags.  
b Partial control is defined as a max PeNAT score of 2 and/or 1-2 vomits, retches, or gags.	
c Uncontrolled is defined as a max PeNAT score of 3-4 and/or > 2 vomits, retches, or 
gags.  
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Table 2.5 
Prevalence of Delayed CINV by Sex and Pubertal Status 
  
Delayed Phase  
  
CINV 
       
CIV 
  
CIN 
  
Male 
 
Female 
  
Male 
 
Female 
  
Male 
 
Female 
Number of patients 
experiencing 
complete control 
(%) 
        
 
Pre Pubertal 18 (35) 8 (31)  39 (75) 12 (46)  18 (35) 9 (35) 
 
Mid Pubertal 15 (35) 5 (38)  24 (56) 6 (46)  15 (35) 5 (38) 
 
Post Pubertal 5 (50) 3 (19)  8 (80) 7 (44)  5 (50) 3 (19) 
 
Number of patients 
experiencing partial 
control (%) 
        
 
Pre Pubertal 5 (10) 5 (19)  7 (13) 11 (42)  5 (10) 4 (15) 
 
Mid Pubertal 5 (12) 3 (23)  15 (35) 2 (15)  5 (12) 3 (23) 
 
Post Pubertal 3 (30) 3 (19)  1 (10) 6 (38)  3 (30) 3 (19) 
 
Number of patients 
experiencing no 
control (i.e. 
uncontrolled) (%) 
        
Pre Pubertal 29 (56) 13 (50)  6 (12) 3 (12)  29 (56) 13 (50) 
 
Mid Pubertal 23 (53) 5 (38)  4 (9) 5 (38)  23 (53) 5 (38) 
 
Post Pubertal 2 (20) 10 (63)  1 (10) 3 (19)  2 (20) 10 (63) 
 
CINV chemotherapy-induced nausea and vomiting, CIV chemotherapy-induced 
vomiting, CIN chemotherapy-induced nausea. 
a Complete control is defined as a max PeNAT score of 1 and/or 0 vomits, retches, or 
gags.  
b Partial control is defined as a max PeNAT score of 2 and/or 1-2 vomits, retches, or gags.	
c Uncontrolled is defined as a max PeNAT score of 3-4 and/or > 2 vomits, retches, or 
gags.   
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Figure 2.1. Level of Delayed CINV Control. Mean (+ sem) delayed CINV scores (out 
of 3, 1= complete control, 2= partial control, 3=uncontrolled) for pre, mid and post 
pubertal male and female participants who developed delayed CINV. In the post pubertal 
group only, there was a significant sex difference; post pubertal females had less control 
of delayed nausea (i.e. experienced more nausea) than post pubertal males *p < .05.   
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uncontrolled delayed CINV. No main effect of Sex was seen in any of the other pubertal 
groups. The chi square analysis also revealed an association between sex and proportion 
experiencing uncontrolled CIN and CINV, for the post pubertal group, X2 (1, N = 26) = 
4.301, p < .05. As shown in Figure 2.2, Post pubertal females demonstrated significantly 
higher proportions of uncontrolled CIN and CINV compared to post pubertal males. All 
other chi square analyses revealed no significant associations.   
2.4 Discussion  
The present study examined putative sex differences in the development of anticipatory, 
acute, and delayed CINV in pediatric oncology patients. Patients were split into three 
groups based on pubertal status: pre-, mid-, and post-pubertal. It was hypothesized that 
sex differences in the development of CINV would only be seen in the post-pubertal age 
group. This post-pubertal sex difference was in fact observed in delayed CINV.  
Notably, in both the pre-, and mid-pubertal patients, no sex differences were seen in acute 
or delayed CINV control. This agrees with multiple studies which found that female sex 
is not a significant predictor of CINV in pediatric oncology patients (Aseeri et al., 2013; 
Dupuis et al., 2017; Holdsworth, Raisch & Frost, 2006; Vol et al., 2016). On the other 
hand, female sex is a well-established risk factor for CINV in adults (Hesketh, 2008; 
Sekine et al., 2013). This seemingly age-dependent sex difference points to some process 
occurring in females during adolescence, making them more susceptible to developing 
CINV. The results from the present study suggest that this said process may in fact be 
puberty.  Puberty begins in females when gonadotropin-releasing hormone (GnRH) is 
secreted by the hypothalamus, which signals the release of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH). This triggers ovarian production of estrogens, which 
are responsible for the behavioral and physiological changes that accompany puberty 
(Dietrich, 2014). Serum estradiol levels are significantly higher in post pubertal girls than 
post pubertal boys, as well as pre-pubertal children of both sexes (Courant et al., 2010). 
This marked rise in estradiol, beginning during puberty, fluctuating throughout the 
menstrual cycle, and lasting until menopause, may be connected to the increase in 
nausea-related phenomena seen in females. In a study identifying risk factors for post- 
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Figure 2.2. Uncontrolled Delayed CINV. Proportions of children experiencing 
uncontrolled CIN, CIV, and CINV in the delayed phase, grouped by sex and pubertal 
status. Post pubertal females demonstrated significantly higher proportions of 
uncontrolled delayed CIN and CINV than post pubertal males,*  p < .05.	
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operative nausea and vomiting (PONV), female sex was identified as the strongest 
patient-related predictor (Fujii, 2009; Gan, 2006). Female sex is also a known risk factor 
for motion sickness susceptibility (Paillard et al., 2013). Moreover, motion sickness has 
been shown to fluctuate throughout the menstrual cycle, in accordance with fluctuating 
estrogen levels (Golding, Kadzere, & Gresty, 2005). Women also report different factors 
than men which contribute to chronic migraine, one of the more prevalent factors being 
nausea (Özge et al, 2014).  
Motion sickness susceptibility and chronic migraine demonstrate additional age-
dependent decreases in the experience of nausea in women but not men. After age 50 – 
60 years, motion sickness susceptibility decreases and nausea no longer predicts chronic 
migraine (Özge et al, 2014; Paillard et al., 2013). Interestingly, this age range 
corresponds to menopause, a time period associated with fluctuations in hormone 
concentrations, particularly the gradual decline of estrogens, which may influence nausea 
responses in women.  
Taken together, the lack of a sex difference in CINV in children, the emergence of a sex 
difference in post-pubertal patients in the present study, a well-established sex difference 
in the adult population, and finally, the menstrual cycle and menopause related changes 
in other nausea related phenomena, all point to some gonadal hormone process operating, 
likely estrogens.  
The finding of a post-pubertal sex difference in delayed CINV in the present study 
provides some evidence that pubertal hormones contribute to the overall sex difference 
seen in the adult population. Though no post-pubertal sex differences were found in 
anticipatory CINV in the present study, we observed a signal that there may be an 
increased chance of anticipatory CINV in post-pubertal females. The lack of significance 
may be due to the particularly small sample size in this group. Notably, the most 
commonly diagnosed cancer in children is leukemia, which is most prevalent in children 
one to four years of age (Greenberg et al., 2015; Canadian Cancer Society, 2016). As 
such, the sample size for the post-pubertal age group was the smallest, and should be re-
examined with a larger sample size in future studies.  
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Some limitations of the present analysis should be mentioned. This is a post hoc analysis 
of data, as such these conclusions can only be considered as hypothesis generation. It is 
also worth discussing the uneven sample sizes in the present study. Due to the large 
proportion of leukemia patients, which is seen predominantly in young children, the 
sample sizes in each pubertal group are substantially varied, with the post pubertal groups 
being the smallest (10 males and 16 females). Further, the original studies were not 
primarily designed to investigate sex differences within each pubertal group. Therefore, 
cut-offs for each pubertal group could only be determined retrospectively, using 
established norms for precocious and late-onset puberty. Future studies should examine 
this research question with a focus on puberty so that clinician-defined pubertal status 
determination is part of the study’s methodology, as well as with larger and more evenly 
divided sample sizes. Limitations of the original studies include their observational nature 
as well as the possibility of selection bias. It is possible that patients who experienced 
more severe CINV were more likely to participate in the studies. Additionally, the studies 
are limited by the subjective nature of self-report by patients or their parents. However, 
the PeNAT has been validated and has shown to be a reliable and accurate indicator of 
nausea in pediatric patients (Dupuis et al., 2006).  
2.4.1 Conclusions 
It was hypothesized that post pubertal female patients would show less CINV control 
than post pubertal males, in the anticipatory, acute, and delayed phases. It was found that 
post pubertal female patients exhibited significantly less CINV control than post pubertal 
male patients. This sex difference was particular to the delayed phase, and was not seen 
in the anticipatory or acute phases. The present findings provide support for a post 
pubertal CINV sex difference, and provide some indication that gonadal hormones may 
be the underlying factor for the observed sex difference in CINV in adults. This study 
also indicates female sex as a possible risk factor for CINV in the post-pubertal pediatric 
population.  
The effects of CINV on individuals experiencing chemotherapy can be debilitating and 
extremely discouraging. Although there are a number of known risk factors for 
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developing CINV in the adult population, research on risk factors in children up until this 
point has been scarce. Developing a comprehensive understanding of the risk factors for 
CINV in children will provide a stronger foundation for targeted CINV prophylaxis and, 
ultimately, will alleviate some of the stress and discomfort that accompany 
chemotherapy. 
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Chapter 3 
3 The Effect of the Estrous Cycle on the Development of 
Anticipatory Nausea (AN) in Female Rats 
3.1 Introduction 
3.1.1 Anticipatory nausea 
Chemotherapy treatment largely contributes to survival rates in cancer patients, due to its 
cytotoxic and antineoplastic effects. Unfortunately, chemotherapy also has several 
undesirable side effects, including nausea and vomiting. Chemotherapy-induced nausea 
and vomiting (CINV) are reported as among the most debilitating and distressing 
treatment-related effects (Aapro, Molassiotis, & Olver, 2005; Molassiotis, 2005). As a 
result, many patients develop anticipatory CINV whereby they are conditioned to 
experience nausea and vomiting in anticipation of the chemotherapy administration. The 
prevalence of anticipatory CINV reported in the literature ranges from 8%–30% of 
patients (Molassiotis et al., 2016; Morrow et al., 1998).  It is posited that anticipatory 
CINV develops through classical conditioning (Bovbjerg, 2006; Stockhorst, 
Steingrueber, Enck, & Klosterhalfen, 2006). The chemotherapy acts as the unconditioned 
stimulus, which elicits nausea and vomiting, the unconditioned response. The physical 
hospital or room acts as the conditioned stimulus and after repeated pairings, these 
environmental stimuli alone can elicit nausea and vomiting (Tyc, Mulhern, Barclay, 
Smith, & Bieberich, 1997). The prevalence and severity of this problem are the basis for 
the development of an animal model of anticipatory CINV (Limebeer, et al., 2006; 2008; 
Rodriguez, Lopez, Symonds, & Hall, 2000). 
3.1.2 Animal model 
A rat model of anticipatory CINV, coined anticipatory nausea (AN) for the purpose of 
this model, has been well established and is used as a preclinical tool to study possible 
treatments (Limebeer et al., 2006; 2008). The model uses the toxin lithium chloride 
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(LiCl), a nausea-inducing drug as the unconditioned stimulus, and a distinctive context as 
the conditioned stimulus. This paradigm demonstrates rats’ ability to associate toxin-
induced nausea with the context in which they experienced it. Rats are injected with LiCl 
and placed in a distinctive context immediately after injection. On the test day, rats are 
placed in the distinctive context drug free, and observed for the disgust behaviours of 
gaping, chin rubbing, paw treading, and forelimb flails. Rats are non-emetic species, so 
gaping has been well established as a reliable and selective indicator of nausea in rats 
(Parker & Limebeer, 2006). Gaping is seen when rats are exposed to drugs known to 
have emetic properties, i.e, cause vomiting in species that have this reflex (Parker & 
Limebeer, 2006; Travers and Norgren, 1983). A number of studies have shown that a 
distinctive context comes to elicit gaping responses in rats after it is paired with injections 
of LiCl (Cloutier, Cross-Mellor, Kavaliers, & Ossenkopp, 2011; Limebeer et al., 2006; 
2008; Rodriguez et al., 2000). Disgust behaviours are also elicited by aversive tastes such 
as bitter quinine (Grill & Berridge, 1985; Grill & Norgren, 1978). This well-established 
animal model is a valuable pre-clinical tool for examining possible risk factors and 
treatments for AN.   
3.1.3 Sex differences and estrogens 
Female sex is a known risk factor for AN in adult cancer patients undergoing 
chemotherapy. Women are significantly more likely to develop symptoms and less likely 
to achieve control (Fetting et al., 1983; Hilarius et al., 2012; LeBaron, Zeltzer, LeBaron, 
Scott, & Zeltzer, 1988). Women under the age of 50 are at particular risk for developing 
AN. Animal studies, using the rat model of AN, have demonstrated this sex difference as 
well. Female rats demonstrated significantly more conditioned gaping behaviour than 
male rats at three different doses of LiCl (64, 96, or 128 mg/kg) (Cloutier, Kavaliers, & 
Ossenkopp, 2017). 
Although this sex difference is well established, further exploration is necessary to 
examine the mechanism(s) underlying this difference. It has been suggested that gonadal 
hormones, specifically estrogens, play a role in this etiology. Estrogens may be 
implicated in the formation of conditioned disgust through the attenuation of conditioned 
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learning, or by facilitating nausea itself. Estradiol has been found to produce both 
conditioned taste avoidance when paired with a novel sucrose taste, as well as 
conditioned disgust responses to the sucrose taste (Ossenkopp, Rabi, & Eckel, 1996). 
Estradiol has also been shown to enhance the acquisition of LiCl-induced conditioned 
taste aversion (CTA) in castrated male rats (Lin, Tsai, Tai, & Yeh, 2015).  This may 
occur because of estradiol’s illness-inducing properties, which have been seen in humans 
(Goodman & Gilman, 1975) as well as animal studies (Ganesan & Simpkins, 1991). 
Estrogens also have stimulatory effects on the serotonergic system. Acute estradiol 
administration to ovariectomized rats increases serotonin levels in a number of brain 
regions, including the hippocampus (Johnson & Crowley, 1983). Serotonin (specifically 
5-HT3) antagonism has well-established anti-emetic effects, thus implicating the 
serotonergic system in the production of nausea and vomiting (Hesketh, 2000). 
Therefore, estrogens may increase nausea and vomiting through a downstream 
serotonergic process. 
Interestingly, estrogens—and consequently—serotonin, have stimulatory effects on 
hippocampal neurogenesis (Mahmoud, Wainwright, & Galea, 2016). There is no shortage 
of research on the involvement of the hippocampus in learning and memory (Josselyn, 
Kohler, & Frankland, 2015; Rosenbaum, Winocur, & Moscovitch, 2001; Winocur, 
Moscovitch, & Sekeres, 2013). While not the sole structure responsible for memory, the 
hippocampus has strong connections to spatial memory (Moser, Rowland, & Moser, 
2015). Circulating estrogen levels are positively correlated with cell proliferation and 
hippocampal neurogenesis in the female rat. Adult female rats have significantly more 
newly proliferating cells in the dentate gyrus during proestrus in comparison to diestrus 
(Pawluski, Brummelte, Barha, Crozier, & Galea, 2009). Recent evidence has suggested 
that this estrogenic effect on the hippocampus may be mediated by serotonin (Mahmoud, 
Wainwright, & Galea, 2016). Thus, connecting estrogens to serotonin, which may have 
some involvement in enhancing both nausea and vomiting, and learning and memory, 
through different pathways. 
There is some evidence that suggests estrogens are involved in learning and memory 
through a rapid mechanism that is controlled by intracellular signaling (Frick et al., 
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2004). These effects have been seen in rodents specifically when estradiol is administered 
shortly after the acquisition phase of a learning task, implicating the early phase of 
memory formation.  Additionally, these results have been extended to human research; 
estradiol levels are positively correlated to working memory performance in women of 
reproductive age (Hampson & Morley, 2013).  
Studies have also shown that estradiol improves memory by potentiating glutamatergic 
and cholinergic activity. Administration of both 17 β-estradiol and estrone into the 
hippocampus of female ovariectomized mice improved retention of T-maze footshock 
avoidance (Farr, Banks & Morley, 2000). As well, normally subthreshold levels of 
estradiol become effective at improving memory retention when co-administered with 
either cholinergic or glutamatergic agnoists. (Farr, Banks, & Morley, 2000).  Estradiol 
treatment in ovariectomized female rats also leads to increased hippocampal dendritic 
spine densities, further supporting the link between estrogens and memory (Woolley & 
McEwen, 1993).     
3.1.4 Estrous cycle 
The reproductive cycle of female rats is known as the estrous cycle. The typical rat 
estrous cycle lasts four days and consists of estrus, metestrus, diestrus, and proestrus 
(Long & Evans, 1922). Estrogen reaches peak levels at proestrus, while diestrus consists 
of baseline estrogen levels. The estrous cycle can be tracked by collecting samples of 
vaginal secretion and examining cell type and quantity in these samples. Thus, the effects 
of estrogens on various behaviours can be determined by tracking the rats’ estrous cycle, 
and quantifying behaviours on specific days of the cycle. Rats in the current study were 
conditioned and tested during proestrus, a period of high estrogen circulation, or diestrus, 
a period of low estrogen circulation.  
3.1.5 Current study 
While sex differences in AN and conditioned disgust have been established in the human 
as well as animal population, further research is required to determine how estrogens 
modulate this phenomenon. The current study investigated possible explanations as to 
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why females are more prone to AN than males. Understanding the mechanisms 
underlying the sex difference in AN may provide differential prophylactic treatment 
strategies to the male and female populations undergoing chemotherapy.  
The current study examined the effect of the estrous cycle on the formation of AN in a rat 
conditioned disgust model, using an intermediate dose (96 mg/kg) of the nausea-inducing 
toxin, LiCl. Based on reported effects of estrogens in the literature, it was hypothesized 
that rats in proestrus (i.e. high estrogen levels) would demonstrate stronger conditioned 
nausea responses than rats in diestrus (i.e. low estrogen levels).  
3.2 Method 
3.2.1 Animals 
Subjects were 31 naïve female Long-Evans rats (Charles River, Quebec, Canada) 
weighing between 125-150g at the start of the experiment. Rats were pair-housed in 
standard polypropylene cages (45 cm x 22 cm x 20 cm) in a temperature-controlled 
colony room (20 ± 1°C) maintained on a 12:12-h light-dark cycle with lights on from 
07:00 to 19:00 h. All testing took place during the light portion of the light-dark cycle. 
Rats had ad libitum access to ProLab Rat Chow RMH 3000 and water, except while in 
the testing apparatus. All procedures used were carried out in compliance with the 
Canadian Council of Animal Care and approved by the Institutional Animal Care 
Committee of Western University.  
3.2.2 Drugs 
Rats (n=15-16/group) were injected intraperitoneally with 96 mg/kg 0.15M LiCl, or 10 
ml/kg 0.9% NaCl. All conditioning and testing took place immediately after drug 
administration. Doses were based on those employed in previous studies examining the 
effect of the drug (Cloutier et al., 2017; Ossenkopp, Biagi, Cloutier, Kavaliers, & Cross-
Mellor, 2011).  
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3.2.3 Materials and apparatus 
The context-conditioning apparatus was an opaque Plexiglas chamber (22.5 cm x 26 cm x 
20 cm) with a gray lid that rested on a transparent glass plate. Below the chamber, a 
mirror was mounted at a 45° angle to allow for viewing of the ventral surface of the rats. 
Rats were tested in a darkened room with two 40W red lights placed below the glass plate 
(see Figure 3.1). This lighting set up was to ensure testing environment was distinctive. 
Behavioral responses during the conditioning days and test day were videotaped with a 
video camera (Sony DCR-DVD201; London, Ontario) located 1 m from the mirror.  
3.2.4 Estrous cycle determination 
Reference images for determination of estrous cycle phase can be seen in Figure 3.2. Rats 
were acclimatized to their home cages for one week and then handled on three separate 
occasions. Following handling, the estrous cycle was tracked daily at the same time each 
day for approximately 14 days. The estrous cycles were tracked by the vaginal smear 
technique. This involved sampling the cells of the vaginal canal with sterile saline using a 
pipette. The recovered solution (approximately 20 µl) containing cells was then placed on 
microscope slides for later determination of estrous cycle phase. This was done using a 
phase-contrast microscope with 10X magnification. Proestrus was determined by 
scattered distribution of predominantly cornified cells and the presence of nucleated cells. 
Diestrus was identified by the reduction in the number of cells and the presence of 
leukocytes (Marcondes, Bianchi, & Tanno, 2002). Vaginal smears were obtained on a 
daily basis for a period of three full estrus cycles prior to testing, after which rats were 
divided in proestrus or diestrus groups.  All rats used in this study exhibited a regular 4-
day cycle.  
3.2.5 Experimental procedure 
The experimental procedure is summarized in Figure 3.3. The experiment consisted of 
two phases: a conditioning phase consisting of four days spaced 96 hours apart, and a 
drug-free test day, 96 hours following the final conditioning day. There were four  
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Figure 3.1. Distinctive Context. On conditioning days, rats are injected with either 96 
mg/kg LiCl or 0.9% NaCl and immediately placed in this distinctive context for 30 
minutes. On test day, rats are placed in this distinctive context drug-free. 
 
Figure 3.2. Estrous Cycle Phases. Sample slides for each estrous cycle phase. 
Metestrus consists of approximately equal proportions of cell types, many leukocytes, 
some cornified cells, and some nucleated cells. Diestrus consists of many small 
leukocytes, which often branch near edges of slides. Proestrus consists of large clumps 
of round, nucleated cells. Estrus consists of sheets of cornified cells and few to no 
nuclei. Phases of interest for this study (Proestrus and Diestrus) are shown in boxes. 
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Day:  1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17 
 
 
 
 
 
 
Figure 3.3. Experimental Procedure. On each conditioning day, rats are injected with 
96 mg/kg LiCl or 0.9% NaCl and immediately placed in the distinctive context. 
Conditioning days are spaced 96 hours apart to ensure rats are consistently conditioned 
during the phase of each rats’ respective group (proestrus or diestrus). Test day occurs 96 
hours following the final conditioning day, where rats are placed into the distinctive 
context drug-free.		
 
 
 
 
 
 
 
 
 
 
Conditioning Days (1, 5, 9, 13) 
• Injected intraperitoneally with either 96 mg/kg LiCl or 0.9% 
NaCl 
• Immediately placed in distinctive context for 30 min  
          Test Day (17) 
• Placed into context drug-
free for 10 min  
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experimental groups (n= 7-8/group). Half of the rats were conditioned and tested during 
diestrus, and the other half during proestrus. Of those two groups, half were given 
intraperitoneal injections of 96 mg/kg 0.15 M LiCl, and half were given control injections 
of 0.9% 10 ml/kg NaCl. As shown in Figure 3.4, the four experimental groups were: 
Proestrus+LiCl, Proestrus+NaCl, Diestrus+LiCl, and Diestrus+NaCl.  
3.2.4.1 Conditioning phase 
On each of the four conditioning days (spaced 96 h apart), animals were injected 
intraperitoneally with NaCl (0.9%, 10 ml/kg), or LiCl (0.15 M; 96 mg/kg) depending on 
experimental group. Immediately following drug administration, each animal was placed 
in the distinctive context for 30 minutes. Behaviors were recorded for later scoring using 
the Observer (Noldus Information Technology, Sterling, VA) Event-Recording Program. 
Dependent behavioural variables analyzed consisted of gaping frequency and other 
aversive responses (forelimb flails, paw treads, and chin rubs). Following each exposure 
to the distinctive context, a vaginal smear was obtained from each animal to confirm 
stage of estrous cycle, and the rat was then returned to its home cage.	
3.2.4.2 Drug-free test day 
Ninety-six hours following the final conditioning day, each rat was re-exposed to the 
distinctive context for 10 min on a drug-free test day. Behaviors were video recorded for 
later scoring using the Observer (Noldus Information Technology, Sterling, VA) Event-
Recording Program. Dependent behavioural variables analyzed consisted of gaping 
frequency and the other aversive responses (forelimb flails, paw treads, and chin rubs). 
Immediately following 10-minute exposure to distinctive context, a vaginal smear was 
again obtained to confirm stage of estrous cycle. 
3.2.5 Data analysis 
On the four 30 minute conditioning days and on the 10 minute drug-free Test Day, 
dependent variables included conditioned gaping behaviour, and other aversion-related 
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31 Females
16 Proestrus
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96 
mg/kg 
LiCl
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NaCl
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0.9% 
NaCl
Figure 3.4. Group Designation.  
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behaviours, such as, forelimb flails, paw treading, and chin rubs, and finally, a composite 
score of these aversion-related behaviours (excluding gaping) (Ossenkopp & Mazmanian, 
1985). Gaping was defined as lowering of the jawbone, opening of the mouth, and the 
protrusion of the lower teeth (Limebeer et al., 2006; 2008).  
Data from conditioning days and test day were analyzed separately. Conditioned gaping 
responses and aversion-related behaviours (excluding gaping) on the conditioning days 
were analyzed using separate 2 x 2 x 4 mixed design analysis of variances (ANOVA) 
with two between-subject factors of Drug (at two levels: 96 mg/kg LiCl and 0.9% NaCl) 
and Estrous Cycle Phase (at two levels: proestrus and diestrus), and one within-subject 
factor of Conditioning Day (at four levels: conditioning days 1 to 4). Conditioned gaping 
responses and aversion-related behaviours (excluding gaping) from the drug-free test day 
were analyzed using separate, 2 x 2 ANOVAs. The between-subjects factors were Drug 
(at two levels: 96 mg/kg LiCl and 0.9% NaCl) and Estrous Cycle Phase (at two levels: 
proestrus and diestrus). As this study was exploratory, Fisher’s least significant 
difference (LSD) test was used for post hoc pairwise comparisons. All statistical tests 
used α=0.05 as a significance criterion. Statistical analyses were performed using IBM 
SPSS Statistics 23 for Windows. 
3.3 Results 
3.3.1 Conditioning days 
The frequency of gaping and aversion-related behaviour during the four conditioning 
days were analyzed in order to evaluate the differences in acquisition rate of conditioned 
disgust responses among the experimental groups.  
3.3.1.1 Conditioned gaping behaviour 
The 2 x 2 x 4 mixed design ANOVA revealed a significant effect of Conditioning Day (1 
to 4), F(3, 81) = 5.85, p < .01, and a significant main effect of Drug (NaCl or LiCl), F(1, 
27) = 21.89, p < .001. A significant Conditioning Day x Drug interaction was also found, 
F(3, 81) = 5.85, p < .01. As shown in Figure 3.5, both LiCl groups showed significantly  
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Figure 3.5. Conditioned Gaping Behaviour on Conditioning Days. Mean (± sem) 
frequency of conditioned gaping responses expressed by the 4 groups (Proestrus+LiCl, 
Diestrus+LiCl, Proestrus+NaCl, & Diestrus+NaCl), during the 30-minute conditioning in 
the distinctive context across four conditioning days (96h apart). Both LiCl groups 
showed significantly more gaping behaviour than both NaCl groups (p < .001). Both 
Proestrus+LiCl and Diestrus+LiCl showed increased gaping behaviour across 
conditioning days (p < .01), while Proestrus+NaCl and Diestrus+NaCl did not.  
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higher gaping responses than NaCl groups. Furthermore, there was a monotonic increase 
in gaping frequency for both Proestrus+LiCl and Diestrus+LiCl groups over the four 
conditioning days.  
3.3.1.2 Conditioned aversion related behaviour 
Conditioned aversion-related behaviours not including gaping (forelimb flails, paw 
treads, and chin rubs) were analyzed as a composite score. The 2 x 2 x 4 mixed design 
ANOVA revealed a significant main effect of Drug, F(1, 27) = 5.88, p < .05. As shown in 
Figure 3.6, both LiCl groups showed significantly more conditioned aversion-related 
behaviours than NaCl groups.  No other significant main effects or interactions were 
found.   
3.3.2 Drug-free test day 
3.3.2.1 Conditioned gaping behaviour 
The 2 x 2 between-subjects ANOVA revealed a significant main effect of Drug, F(1,27) 
= 23.48, p < .001. A significant main effect of Phase, F(1,27) = 11.50, p < .01, as well as 
a significant Drug x Phase interaction, F(1,27) = 11.50, p < .01 were found. As shown in 
Figure 3.7, post-hoc pair-wise comparisons (Fisher’s LSD) for phase differences revealed 
that rats in Group Proestrus+LiCl displayed significantly higher frequencies of 
conditioned gaping responses, relative to Diestrus+LiCl, Proestrus+NaCl, and 
Diestrus+NaCl groups (p < .001).   
3.3.2.2 Conditioned aversion related behaviour 
Conditioned aversion-related behaviours not including gaping (forelimb flails, paw 
treads, and chin rubs) were analyzed as a composite score. The 2 x 2 between-subjects 
ANOVA revealed a significant main effect of Drug, F(1, 27) = 19.82, p < .001, and 
significant main effect of Phase F(1, 27) = 4.50, p < .05. No significant interaction was 
found. As demonstrated in Figure 3.8, post hoc analyses (Fisher’s LSD) for phase 
differences revealed that rats in Group Proestrus+LiCl displayed significantly higher  
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Figure 3.6. Conditioned Aversion Related Behaviours on Conditioning Days. Mean 
(± sem) frequency of conditioned aversion related behaviours expressed by the 4 groups 
(Proestrus+LiCl, Diestrus+LiCl, Proestrus+NaCl, & Diestrus+NaCl), during the 30-
minute conditioning in the distinctive context across four conditioning days (96h apart). 
Both LiCl groups demonstrated significantly more aversion related behaviours than both 
NaCl groups (p < .05). No significant conditioning day effects were seen.	
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Figure 3.7. Conditioned Gaping Behaviour on Test Day. Group mean (+ sem) 
frequency of total gaping responses expressed by groups LiCl+Proestrus, LiCl+Diestrus, 
NaCl+Proestrus, and NaCl+Diestrus during the 10 min test in the distinctive context in 
the absence of drug treatment (n= 7-8/experimental group). LiCl treated animals showed 
significantly more gaping than NaCl treated animals ***(p < .001), and LiCl+Proestrus 
showed significantly more gaping than LiCl+Diestrus ***(p < .001). 
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Figure 3.8. Conditioned Aversion Related Behaviour on Test Day. Group mean (+ 
sem) frequency of total aversion related responses (excluding gaping) expressed by 
groups LiCl+Proestrus, LiCl+Diestrus, NaCl+Proestrus, and NaCl+Diestrus during the 
10 min test in the distinctive context in the absence of drug treatment (n= 7-8/ 
experimental group). LiCl treated animals showed significantly more aversion related 
behaviour than NaCl treated animals ***(p < .001), and LiCl+Proestrus showed 
significantly more aversion related behaviour than LiCl+Diestrus *(p < .05). 
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frequencies of conditioned aversion-related behaviours than Diestrus+LiCl (p < .05), 
Proestrus+NaCl (p < .001), and Diestrus+NaCl groups (p < .001).  
3.3.3 Estrous cycle determination 
Following coding of the lavage samples under 10x magnification under the microscope, it 
was confirmed that each rat assigned to the diestrus or proestrus group was in fact 
conditioned and tested during diestrus or proestrus, respectively. No disruptions to 
estrous cycle phases were observed in the rats following drug treatment.	
3.4 Discussion 
The current study investigated the relationship of the estrous cycle with the formation of 
conditioned disgust behaviours in the rodent model of AN, using 96 mg/kg of nausea-
inducing LiCl and a saline control. It was hypothesized that proestrus rats would show 
greater levels of conditioned disgust responses relative to diestrus rats and this hypothesis 
was supported. Results showed that on the drug free test day, rats conditioned and tested 
during proestrus demonstrated greater levels of conditioned gaping and other aversion-
related behaviours (i.e., forelimb flails paw treads, and chin rubs) relative to rats 
conditioned and tested during diestrus. This finding is consistent with previously 
observed effects of estrogens on other conditioning paradigms (Farr, Banks, & Morley, 
2000; Lin et al., 2015; Ossenkopp et al., 1996).  
Although increased levels of estrogens were associated with increased conditioned 
disgust responses on test day, no such effects were seen on the conditioning days. That is, 
proestrus and diestrus rats learned the conditioned disgust behaviours at the same rate. 
During the conditioning trials, rats were injected with LiCl and immediately placed into 
the distinctive context. This allowed the association between feelings of nausea and the 
distinctive context to form, which then manifested as conditioned gaping. When the rats 
were placed into the distinctive context drug-free on test day, the presence of conditioned 
gaping behaviour indexed this learned association. In the current study, estrous cycle 
phase effects were only seen on drug-free test day. This suggests that estrogen enhances 
the memory component of the AN model, rather than augmenting learning during 
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conditioning trials. This inference is supported by numerous studies that have 
demonstrated estradiol’s beneficial effects on hippocampal-dependent spatial memory 
(Al Abed et al., 2016; Barker & Galea, 2010; Frye, Duffy, & Walf, 2007; Sandstrom & 
Williams, 2004; Tuscher, Fortress, Kim & Frick, 2015). Estradiol likely exerts its effect 
on memory by increasing dendritic spine density on CA1 pyramidal neurons, as well as 
increasing proliferation of new neurons in the hippocampus. These effects of estradiol on 
the hippocampus were first discovered by Woolley and McEwen (1993) and have since 
been replicated by numerous labs (Barha, Dalton & Galea, 2010; Frankfurt & Luine, 
2015: Frick et al., 2004). 17β-estradiol specifically dose-dependently upregulates cell 
proliferation in the dentate gyrus of adult female rats (Barha et al., 2009). Both ER-α and 
ER- β have been shown to be involved in estradiol-increased cell proliferation in the 
dentate gyrus of adult female rats (Mazzucco et al., 2006). With regards to non-spatial 
working memory, the effects of estradiol are more complex. Studies have shown that 
injections of low-dose estradiol facilitates non-spatial working memory, while high-dose 
estradiol impairs it (Barha et al., 2010; Wide, Hanratty, Ting, & Galea, 2004). The effects 
of estrogens on the brain are both region and memory task specific. Estrogens seem to 
facilitate hippocampal-dependent learning, but attenuate striatal-dependent learning 
(Davis, Jacobson, Aliakbari, & Mizumori, 2005). This is reiterated in the study by Fader, 
Johnson, and Dohanich (199), that demonstrated that estrogen improves spatial working 
memory, but not reference memory. Thus, though the enhancing effects of estrogen on 
hippocampal-dependent memory specifically are well documented (Joesselyn et al., 
2015; Rosenbaum et al., 2001; Winocur et al., 2013), estrogen’s effects on other types of 
memory are less clear.  
The present study demonstrated a positive relationship between estrogen levels and 
presumed memory for learned disgust, but perhaps this result would be better explained 
by the increase in nausea/disgust itself during conditioned trials. As demonstrated in 
Figure 3.5, Proestrus+LiCl rats do have a higher gaping response frequency than 
Diestrus+LiCl rats, albeit this was not significant. It is possible that with a larger sample 
size and thus more power, a significant effect would emerge. In this case, estrogens 
would be implicated not only in the memory of the association between the context and 
disgust, but also in the acquisition of this association. This explanation is plausible as 
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there is substantial research connecting estrogens to nausea and malaise in general, such 
as estradiol-related increases in nausea during pregnancy (with contributions from 
progesterone as well), or in women taking oral contraceptives (Ganesan, 1994; Lagiou et 
al., 2003; Matchock, Levine, Gianaros, & Stern, 2008). Since estrogens have been linked 
to nausea in other studies, it is possible that in the current study, the increased levels of 
estrogen in proestrus rats is causing greater disgust-related behaviours during 
conditioning days. Future studies should examine this possibility by using larger sample 
sizes. 
Past studies measuring exact hormone levels in rats have shown that during proestrus, 
estradiol levels in serum are approximately 90 pg/mL, while during diestrus estradiol 
levels are about 30 pg/mL (Faccio et al., 2013). This represents a marked difference in 
estradiol levels between the two phases. Progesterone levels in serum however, average 
at about 35 ng/mL during proestrus, and 20 ng/mL during diestrus (Faccio et al., 2013). 
Although the present study did not measure hormone levels in the rats, this evidence 
suggests that the change in behaviour seen in proestrus rats is likely due to the large 
difference in estradiol levels compared to diestrus rats. The difference in progesterone 
levels from proestrus to diestrus is not as pronounced, and likely not causing the 
increased AN behaviours seen in proestrus rats.  
Tracking the estrous cycle is a clever way of using female rats’ natural ebb and flow of 
hormones to examine the putative effects of hormones on certain behaviours. This 
method has the advantage of being relatively non-invasive and doesn’t put the animal 
through the stress of a surgery. The caveat is, however, that the phases of the estrous 
cycle are a relative measure of estrogen and progesterone, and do not provide an exact 
measure of the hormones. Thus, although it is likely estrogens causing the increased AN, 
the present study does not definitively prove this. The current methodology was used due 
to the exploratory nature of the study. Now that additional support has been provided for 
estrogen’s role in AN, a follow up study should explore this further by means of 
ovariectomy and estrogen and/or progesterone replacement.   
AN is not the only syndrome in which women exhibit higher incidences of nausea than 
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men. In a study identifying risk factors for post-operative nausea and vomiting (PONV), 
female sex was identified as the strongest patient-related predictor (Fujii, 2009; Gan, 
2006). Female sex is also a known risk factor for motion sickness susceptibility (Paillard 
et al., 2013), which is highly relevant to the current study given that provocative 
vestibular stimulation has been used as the unconditioned stimulus in similar conditioned 
disgust paradigms (Cordick, Parker, & Ossenkopp, 1999; Limebeer et al., 2008; 
Ossenkopp et al., 2003). Moreover, motion sickness has been shown to fluctuate 
throughout the menstrual cycle, in accordance with fluctuating estrogen levels (Golding, 
Kadzere, & Gresty, 2005).  
Most studies employing animal models of AN have used male rats, with some recent 
studies examining putative sex differences (Cloutier et al., 2017). The existence of sex 
differences in multiple types of nausea highlights the importance of the use of female 
rats, and taking the estrous cycle into account, in the animal model for AN. In addition to 
context, taste cue is another stimulus that can elicit a conditioned disgust response when 
paired with a toxin. Taste aversion/avoidance paradigms, where rats are injected with a 
salient taste cue combined with a LiCl to induce nausea, produce a similar conditioned 
disgust effect to context-conditioning (Parker et al., 2006; Cloutier, Cross-Mellor, 
Kavaliers, & Ossenkopp, 2011). The effect of the estrous cycle has yet to be explored in 
taste aversion/avoidance paradigms. Future studies should examine a putative role of 
estrogen in the development of conditioned taste aversion/avoidance.   
Developing a comprehensive understanding of AN and its relation to the estrous cycle 
will provide a strong foundation for which treatment and prevention efforts can be 
directed. At present, the best-known strategy to defend against AN is to prevent it from 
developing in the first place, by controlling acute and delayed CINV immediately using 
5-hydroxytryptamine3 (5-HT3) and neurokinin1 receptor (NK1) antagonists. These 
medications are well-documented to alleviate vomiting, but their effects on nausea are 
more complicated (Miner & Sanger, 1986; Costall, Domeney, Naylor, & Tattersall, 1986; 
Sanger & Andrews, 2006). And further, once it does develop, AN is refractory to anti-
emetic medication for the most part. This study lends support to the hypothesis that 
estrogen augments the learning of this conditioned nausea. If this idea is further 
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supported, it is possible estrogen antagonism could become a new avenue to explore in 
terms of pharmacological treatment options. Additionally, women may be able to prevent 
the severity of AN by adjusting their chemotherapy schedule around their menstrual 
cycle, such that the treatments never coincide with the days where estrogen levels are the 
highest. Due to the clinical relevance of AN, further human studies are necessary in order 
to explore this phenomenon. 
3.4.1 Conclusions 
It was hypothesized that proestrus rats would condition higher levels of disgust responses 
relative to diestrus rats in the rodent model of AN. It was found that proestrus rats 
exhibited significantly stronger conditioned disgust responding via gaping and other 
aversion-related behaviours (i.e., chin rubs, paw treads, and forelimb flails), when re-
exposed to a distinctive context previously paired with the toxin, LiCl.  This estrous cycle 
phase effect was not seen during conditioning days, which suggests estrogens may be 
impacting memory for the conditioned association, rather than the learning process itself. 
The present findings provide support that estrogens may contribute to the higher 
incidence of AN in females, a finding which should be further examined. 
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Chapter 4 
4 General Discussion 
Cancer patients list chemotherapy-induced nausea and vomiting (CINV) as one of the 
most distressing and bothersome events that negatively affects quality of life. While both 
sexes do experience this distressing side-effect, evidence suggests that there is a sex 
difference in the prevalence and severity of CINV, where females have been shown to be 
more susceptible relative to males (Molassiotis, Stamataki, & Kontopantelis, 2013; 
Sekine, Segawa, Kubota, & Saeki, 2013; Warr, 2014;). This sex difference is seen in all 
phases of CINV, which includes acute, delayed, and anticipatory. In the animal model of 
anticipatory nausea (AN), which was developed to study the anticipatory phase of CINV, 
a sex difference in favour of females has also been seen (Cloutier, Kavaliers, & 
Ossenkopp, 2017). Although this sex difference is well established, the reason behind the 
increase in CINV seen in females remains unknown. The current thesis explored the 
mechanism behind the known sex difference in CINV using two diverse approaches.  
In Chapter 2, sex differences in the development of anticipatory, acute, and delayed 
CINV in pediatric oncology patients were examined. Patients were split into three groups 
based on pubertal status: pre-, mid-, and post-pubertal. It was hypothesized that sex 
differences in the development of CINV would only be seen in the post-pubertal age 
group, due to the higher levels of estrogen in this group of females. This post-pubertal 
sex difference was in fact observed in delayed CINV. Notably, in both the pre-, and mid-
pubertal patients, no sex differences were seen in acute or delayed CINV control. This 
agrees with multiple studies which found that female sex is not a significant predictor of 
CINV in pediatric oncology patients (Aseeri, Mukhtar, Khansa, Elimam, Jastaniah, 2013; 
Dupuis et al., 2017; Holdsworth, Raisch & Frost, 2006; Vol et al., 2016). As previously 
established, female sex is a risk factor for the development of CINV in the adult oncology 
population. The present study demonstrated that the observed sex difference in CINV 
may in fact emerge around adolescence, which indicates the involvement of sex steroids. 
In terms of anticipatory CINV, no significant sex differences were seen in the pre-, mid-, 
or post-pubertal groups. However, although this difference was not significant, post-
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pubertal females did show substantially higher proportions of anticipatory CINV than 
males. Since uncontrolled acute or delayed CINV is a risk factor for the development of 
anticipatory CINV (Lohr, 2008), and post-pubertal females did demonstrate significantly 
less delayed CINV control than males, it is possible that this post-pubertal sex difference 
in anticipatory CINV would prove to be significant with a larger sample size.  
In order to further investigate estrogen’s effects, in Chapter 3, the rodent model of 
anticipatory nausea (AN) was employed to test whether the estrous cycle influences the 
ability of female rats to form associations between a distinct context and feelings of 
disgust (i.e., AN). The estrous cycle is the reproductive cycle of the female rat, and 
consists of a cyclical rise and fall of estrogen and progesterone. The effects of estrogens 
on various behaviours can be determined by tracking the rats’ estrous cycle, and 
quantifying behaviours on specific days of the cycle. As predicted, on the drug free test 
day, rats conditioned and tested during proestrus (high estrogen levels) demonstrated 
greater levels of aversion-related disgust behaviour relative to rats conditioned and tested 
during diestrus (low estrogen levels). And further, this effect was not seen on 
conditioning days, suggesting estrogen is acting on the memory component of 
conditioned disgust, rather than on the learning of the toxin-induced nausea itself. To the 
best of our knowledge, this was the first study to demonstrate a significant estrous cycle 
difference in conditioned disgust using the rodent model of AN. The results of this study 
strengthen the notion that estrogens are involved in nausea in general, and also suggest 
estrogens plays a role in CINV. This implies that females’ greater likelihood to 
experience CINV may be in part due to their higher levels of circulating estrogens, in 
comparison to males.   
Taken together with the findings of Chapter 2, a strong indication for the involvement of 
gonadal hormones has been established. The results of this thesis imply that estrogens 
affect the development of CINV in the delayed phase, through increasing nausea itself, 
and in the anticipatory phase, through increasing both nausea, and memory of the 
conditioned nausea. 
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One caveat of this thesis is that it does not definitively prove that estrogen is in fact the 
gonadal hormone contributing to the effects shown. It may be possible that another 
prominent female hormone, progesterone, is having an effect. While this possibility 
cannot be eliminated without conducting a study involving direct hormone manipulation, 
a number of findings in the literature suggest that progesterone has either minimal or 
unpredictable effects on learning and memory or nausea. In a study examining the effects 
of estradiol and progesterone on the acquisition of conditioned taste aversion (CTA), it 
was found that estradiol, but not progesterone affected the acquisition of CTA learning. 
In fact, some studies have shown that progesterone actually impairs performance of 
spatial and working memory, and avoidance tasks in female rats (Braden et al., 2015; Fry 
& Sturgis, 1995; Johansson et al., 2002). There is also evidence that women taking 
progesterone as part of hormone therapy for menopause have an increased risk of 
dementia as well as other cognitive impairments (Coker et al., 2010; Shumaker et al., 
2003). With regards to nausea, the research on progesterone’s connection has yielded 
mixed results. In some studies, progesterone has been shown to have minimal 
connections with the its development. In a study assessing pregnancy hormone levels in 
relation to nausea, it was found that estradiol was positively associated with nausea with 
or without vomiting, while no evidence was found for progesterone’s connection to 
nausea during pregnancy (Lagiou et al., 2003). Conversely, there has been some research 
which has shown that the elevation of the combination of progesterone and estrogen are 
associated with the gastric dysrhythmias that correlate to pregnancy-related nausea 
(Walsh, Hasler, Nugent, & Owyang, 1996). In a literature review on Hyperemesis 
Gravidarum (HG), a condition which causes severe nausea and vomiting in early 
pregnancy, it was concluded that progesterone’s connection to this condition is weak to 
inconclusive, while estrogens are likely causally related to HG (Verberg, Gillott, Al-
Fardan, & Grudzinskas, 2005).  
These studies strongly suggest that elevated progesterone is not the reason for the 
increase in CINV in females in comparison to males. While estrogen’s involvement 
cannot be definitively proven without performing hormone manipulation experiments, 
much of the literature points to it being a key contributing factor. Estrogen can increase 
the number of dopamine receptors in the brain, while certain antiemetic drugs such as 
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droperidol are designed to inhibit these dopamine receptors (Hruska & Sibergeld, 1980; 
Tornetta, 1977). This suggests that estrogen may influence nausea through a dopamine-
mediated pathway. It has also been postulated that estrogen sensitizes vomiting centers 
such as the area postrema and triggers nausea. The area postrema is a circumventricular 
medullary structure implicated in the detection of toxins, such as LiCl, and acts as a 
vomit-inducing center. Following exogenous administration of estradiol benzoate, 
markers for neuronal activity are activated in the area postrema. In addition, area 
postrema lesions eliminate the hypophagia expressed by male rats exposed to chronic 
estradiol treatment (Bernstein, Courtney, & Braget, 1986). An intact area postrema is 
critical for taste avoidance and aversion learning with LiCl (Eckel and Ossenkopp, 1996; 
Ossenkopp & Eckel, 1994;1995). Estrogen can also act as the unconditioned stimulus in a 
CTA learning paradigm (Hintiryan, Foster, Chambers, 2009; Ossenkopp et al., 1996), and 
it can enhance LiCl-induced CTA (Ganesan & Simpkins, 1991).  
While further research is required to determine estrogen’s specific involvement in CINV, 
there is no shortage of research on the connection between estrogens and nausea and 
vomiting in general. The results of the present thesis, along with the number of studies 
that have drawn connections between estrogens and nausea, point to estrogens being a 
key contributor to the sex difference seen in CINV in cancer patients.  
4.1 Conclusions 
In the present thesis, the possible mechanism behind the sex difference seen in CINV was 
explored. This was done using two diverse approaches: a post hoc data analysis of CINV 
in a pediatric oncology patient population, and a rodent model of AN to examine the 
influence of the estrous cycle on the establishment of context-based disgust conditioning. 
The human post hoc analysis revealed female pediatric patients demonstrate less delayed 
CINV control than male patients, specifically in the post-pubertal age group. Both pre- 
and mid-pubertal patients did not show a sex difference in either anticipatory, acute, or 
delayed CINV. The rodent study showed that rats conditioned and tested during a period 
of high estrogen circulation (i.e., proestrus) demonstrate increased conditioned-disgust 
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behaviours relative to rats conditioned and tested during a period of low estrogen 
circulation (i.e., diestrus).  
Future studies might extend these animal results by examining AN in rats in varying 
pubertal stages, in both females and males. Given the results from the human study which 
suggest a sex difference only appears once patients reach puberty, studying this theory in 
rodents would further strengthen the animal model of AN as a useful preclinical tool. 
Furthermore, the effects of ovariectomy and replacement of estrogen and/or progesterone 
should be evaluated in female rats, as this would provide a clearer indication of which 
gonadal hormone causes increased conditioned nausea-related behaviour. Future clinical 
studies should examine this research question with a focus on puberty so that clinician-
defined pubertal status determination is part of the study’s methodology, as well as with 
larger and more evenly divided sample sizes. 
Until the mechanism behind the sex difference in CINV is completely understood, 
treatment of and prophylaxis for CINV will be suboptimal, and will continue to have a 
profound impact on cancer patients’ lives. The current thesis provides substantial support 
to suggest that increased levels of estrogens in female patients may be the underlying 
cause for the observed sex difference. These results provide a basis for future studies to 
explore both direct hormone manipulation in the animal model, and hormone assays in 
the clinical population, in order to further elucidate estrogen’s possible effects. 
Uncovering this mechanism will ultimately help to alleviate the burden of CINV on 
cancer patients, and the present thesis lays the groundwork that future studies can build 
on.  
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